Supernus Pharmaceuticals (NASDAQ:SUPN) Director Frederick M. Hudson Sells 7,457 Shares

Key Points

• Supernus Pharmaceuticals Director Frederick M. Hudson sold 7,457 shares at an average price of $42.26, totaling approximately $315,132.82, which decreased his stake in the company by 13.87%.
• Supernus Pharmaceuticals' stock rose by 0.7% to $42.99, with an average trading volume of 682,108 shares compared to its usual volume of 638,685.
• Several analysts have recently upgraded Supernus Pharmaceuticals, including Cantor Fitzgerald, which raised its price target from $42.00 to $46.00 and assigned it an "overweight" rating.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Frederick M. Hudson sold 7,457 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total value of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares in the company, valued at approximately $1,956,933.82. This represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN traded up $0.5490 during trading hours on Thursday, hitting $43.2290. The company's stock had a trading volume of 346,095 shares, compared to its average volume of 637,682. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of 37.81 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $43.73. The business has a 50-day simple moving average of $34.94 and a 200-day simple moving average of $33.65.

Analysts Set New Price Targets

Several research firms recently issued reports on SUPN. Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $41.00.

Institutional Trading of Supernus Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Ashford Capital Management Inc. boosted its position in Supernus Pharmaceuticals by 1.4% during the 2nd quarter. Ashford Capital Management Inc. now owns 574,372 shares of the specialty pharmaceutical company's stock valued at $18,104,000 after acquiring an additional 7,816 shares in the last quarter. Public Sector Pension Investment Board boosted its position in Supernus Pharmaceuticals by 0.3% during the 2nd quarter. Public Sector Pension Investment Board now owns 220,304 shares of the specialty pharmaceutical company's stock valued at $6,944,000 after acquiring an additional 573 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Supernus Pharmaceuticals by 5.7% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 61,936 shares of the specialty pharmaceutical company's stock valued at $1,954,000 after acquiring an additional 3,336 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Supernus Pharmaceuticals by 255.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,245 shares of the specialty pharmaceutical company's stock valued at $134,000 after acquiring an additional 3,051 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $248,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.